000892447 001__ 892447
000892447 005__ 20210831151939.0
000892447 0247_ $$2doi$$a10.1002/mds.28608
000892447 0247_ $$2ISSN$$a0885-3185
000892447 0247_ $$2ISSN$$a1531-8257
000892447 0247_ $$2Handle$$a2128/28566
000892447 0247_ $$2altmetric$$aaltmetric:105260253
000892447 0247_ $$2pmid$$apmid:33942926
000892447 0247_ $$2WOS$$aWOS:000646650300001
000892447 037__ $$aFZJ-2021-02085
000892447 082__ $$a610
000892447 1001_ $$0P:(DE-HGF)0$$aKremer, Thomas$$b0$$eCorresponding author
000892447 245__ $$aLongitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
000892447 260__ $$aNew York, NY$$bWiley$$c2021
000892447 3367_ $$2DRIVER$$aarticle
000892447 3367_ $$2DataCite$$aOutput Types/Journal article
000892447 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1629455611_14502
000892447 3367_ $$2BibTeX$$aARTICLE
000892447 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000892447 3367_ $$00$$2EndNote$$aJournal Article
000892447 520__ $$aBackground: Cerebrospinal fluid (CSF) levels of monoamine metabolites may represent biomarkers of Parkinson's disease (PD).Objective: The aim of this study was quantification of multiple metabolites in CSF from PD versus healthy control subjects (HCs), including longitudinal analysis.Methods: Absolute levels of multiple monoamine metabolites in CSF were quantified by liquid chromatography coupled with tandem mass spectrometry from 161 individuals with early PD and 115 HCs from the Parkinson's Progression Marker Initiative and de novo PD (DeNoPA) studies.Results: Baseline levels of homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were lower in individuals with PD compared with HCs. HVA levels correlated with Movement Disorder Society Unified Parkinson's Disease Rating Scale total scores (P < 0.01). Both HVA/dopamine and DOPAC/dopamine levels correlated with caudate nucleus and raw DOPAC with putamen dopamine transporter single-photon emission computed tomography uptake ratios (P < 0.01). No metabolite changed over 2 years in drug-naive individuals, but some changed on starting levodopa treatment.Conclusions: HVA and DOPAC CSF levels mirrored nigrostriatal pathway damage, confirming the central role of dopaminergic degeneration in early PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Keywords: CSF; Parkinson's disease; biomarker; catecholamine; homovanillic acid; monoamine metabolites; neurotransmitter.
000892447 536__ $$0G:(DE-HGF)POF4-525$$a525 - Decoding Brain Organization and Dysfunction (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000892447 588__ $$aDataset connected to DataCite
000892447 7001_ $$0P:(DE-HGF)0$$aTaylor, Kirsten I.$$b1
000892447 7001_ $$0P:(DE-HGF)0$$aSiebourg-Polster, Juliane$$b2
000892447 7001_ $$0P:(DE-HGF)0$$aGerken, Thomas$$b3
000892447 7001_ $$0P:(DE-HGF)0$$aStaempfli, Andreas$$b4
000892447 7001_ $$0P:(DE-HGF)0$$aCzech, Christian$$b5
000892447 7001_ $$0P:(DE-Juel1)177772$$aDukart, Juergen$$b6
000892447 7001_ $$0P:(DE-HGF)0$$aGalasko, Douglas$$b7
000892447 7001_ $$0P:(DE-HGF)0$$aForoud, Tatiana$$b8
000892447 7001_ $$0P:(DE-HGF)0$$aChahine, Lana M.$$b9
000892447 7001_ $$0P:(DE-HGF)0$$aCoffey, Christopher S.$$b10
000892447 7001_ $$0P:(DE-HGF)0$$aSimuni, Tanya$$b11
000892447 7001_ $$0P:(DE-HGF)0$$aWeintraub, Daniel$$b12
000892447 7001_ $$0P:(DE-HGF)0$$aSeibyl, John$$b13
000892447 7001_ $$0P:(DE-HGF)0$$aPoston, Kathleen L.$$b14
000892447 7001_ $$0P:(DE-HGF)0$$aToga, Arthur W.$$b15
000892447 7001_ $$0P:(DE-HGF)0$$aTanner, Caroline M.$$b16
000892447 7001_ $$0P:(DE-HGF)0$$aMarek, Kenneth$$b17
000892447 7001_ $$0P:(DE-HGF)0$$aHutten, Samantha J.$$b18
000892447 7001_ $$0P:(DE-HGF)0$$aDziadek, Sebastian$$b19
000892447 7001_ $$0P:(DE-HGF)0$$aTrenkwalder, Claudia$$b20
000892447 7001_ $$0P:(DE-HGF)0$$aPagano, Gennaro$$b21
000892447 7001_ $$0P:(DE-HGF)0$$aMollenhauer, Brit$$b22
000892447 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.28608$$gp. mds.28608$$n8$$p1972-1978$$tMovement disorders$$v36$$x1531-8257$$y2021
000892447 8564_ $$uhttps://juser.fz-juelich.de/record/892447/files/mds.28608.pdf$$yOpenAccess
000892447 909CO $$ooai:juser.fz-juelich.de:892447$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000892447 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177772$$aForschungszentrum Jülich$$b6$$kFZJ
000892447 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000892447 9130_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000892447 9141_ $$y2021
000892447 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-30
000892447 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000892447 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-30
000892447 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000892447 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2019$$d2021-01-30
000892447 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-30$$wger
000892447 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-30
000892447 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000892447 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-30
000892447 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000892447 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-30
000892447 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2019$$d2021-01-30
000892447 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-30
000892447 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-30
000892447 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-30$$wger
000892447 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-30
000892447 920__ $$lyes
000892447 9201_ $$0I:(DE-Juel1)INM-7-20090406$$kINM-7$$lGehirn & Verhalten$$x0
000892447 980__ $$ajournal
000892447 980__ $$aVDB
000892447 980__ $$aUNRESTRICTED
000892447 980__ $$aI:(DE-Juel1)INM-7-20090406
000892447 9801_ $$aFullTexts